Latest Articles
Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer - The ASCO Post
Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer The ASCO Post
Published: June 4, 2026, 10:12 p.m.
KPTI: Phase III data in myelofibrosis and endometrial cancer signal major advances and rapid adoption - TradingView
KPTI: Phase III data in myelofibrosis and endometrial cancer signal major advances and rapid adoption TradingView
Published: June 4, 2026, 1:28 p.m.
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 - Karyopharm
Karyopharm to Participate in Webcast Featuring Endometrial Cancer Key Opinion Leader on June 8, 2026 Karyopharm
Published: June 3, 2026, 10:53 p.m.
The same molecular group that slows colorectal cancer drives endometrial cancer in a Lleida study - apd.cat
The same molecular group that slows colorectal cancer drives endometrial cancer in a Lleida study apd.cat
Published: June 3, 2026, 3:47 p.m.
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer - The ASCO Post
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer The ASCO Post
Published: June 3, 2026, 2:49 p.m.
Robin Quivers Announces Remission Following Endometrial Cancer Battle - sekbernews.id
Robin Quivers Announces Remission Following Endometrial Cancer Battle sekbernews.id
Published: June 3, 2026, 2:32 p.m.
Robin Quivers Announces Remission Following Extended Endometrial Cancer Battle - HarianBasis.co
Robin Quivers Announces Remission Following Extended Endometrial Cancer Battle HarianBasis.co
Published: June 3, 2026, 2:31 p.m.
Ibuprofen and endometrial cancer: An observational study finds a positive association. - unicaradio.it
Ibuprofen and endometrial cancer: An observational study finds a positive association. unicaradio.it
Published: June 3, 2026, 8:48 a.m.
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer - Oncodaily
NRG-GY018 at ASCO 2026: Pembrolizumab Plus Chemotherapy Sustains Overall Survival Benefit in Advanced Endometrial Cancer Oncodaily
Published: June 3, 2026, 3:15 a.m.
Sacituzumab govitecan shows encouraging results for aggressive endometrial cancer - MSN
Sacituzumab govitecan shows encouraging results for aggressive endometrial cancer MSN
Published: June 3, 2026, 12:54 a.m.
Link copied to clipboard!